RxDoctor Payments Data

Joey Buquing, MD

Nephrology · Houston, TXNPI 1255335279

Payments from drug & device makers

$11,722in general payments, 2019–2025

Across 571 payments — averaging $20.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • OPKO Pharmaceuticals, LLC$1K
  • Bayer$959
  • Akebia Therapeutics Inc$930
  • Veloxis Pharmaceuticals, Inc.$851
  • AstraZeneca$704
  • plus $5K from 33 others

What the payments were for

  • Speaking & faculty fees$2702%
  • Food & beverage$10,60495%
  • Education$2502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,722 in reported general payments places this provider in the 80th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$178,472
Medicare patients
164
Services billed
2,176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl28$86,112
FarxigaDapagliflozin Propanediol54$65,239
RayaldeeCalcifediol47$62,147
VeltassaPatiromer Calcium Sorbitex34$55,162
KerendiaFinerenone45$51,453
AuryxiaFerric Citrate20$38,619
JardianceEmpagliflozin44$36,170
EliquisApixaban16$20,902
Cinacalcet Hcl56$9,150
Sevelamer Carbonate39$5,798
Calcium Acetate37$3,985
Valganciclovir Hcl14$3,704
Nifedipine ErNifedipine75$2,252
Calcitriol111$2,173
Hydralazine Hcl70$1,218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$704$65,23954 claims
OPKO Pharmaceuticals, LLCRayaldee$1,358$62,14747 claims
BayerKerendia$959$51,45345 claims
Akebia Therapeutics IncAuryxia$930$38,61920 claims
Boehringer IngelheimJardiance$37$36,17044 claims
PfizerEliquis$24$20,90216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →